• About us
• Contact

Advertisement

Organisation › Details

Idorsia (Group)

Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this we will develop Idorsia into Europe's leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland - a European biotech hub - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success. Idorsia was listed on SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 600 highly qualified specialists dedicated to realizing our ambitious targets. *

 

	Start	2017-03-02 established
	Predecessor	Actelion Ltd. (SIX: ATLN)
	Industry	pharmaceutical
	Person	Clozel, Jean-Paul (Idorsia 20403 CEO + Co-Founder before Actelion)
	Person 2	Muller, André C. (Idorsia 202407 CEO formerly CFO before Actelion 201309– CFO before Pierre Fabre CFO)
	Region	Allschwil BL
	Country	Switzerland
	Street	91 Hegenheimermattweg
	City	4123 Allschwil BL
		Address record changed: 2024-01-05
Basic data	Employees	E: 501 to 1,000 (2019-12-31)
	Currency	CHF
	Annual sales	24,000,000 (revenue, net, consolidated (2019) 2019-12-31)
	Profit	-494,000,000 (2019-12-31)
	Cash	263,000,000 (2019-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Idorsia (Group)

• [1] Idorsia Ltd.. (7/1/24). "Press Release: Idorsia’s Jeraygo (aprocitentan) Approved in Europe as First and Only ERA for the Treatment of Resistant Hypertension". Allschwil....
• [2] Idorsia Ltd.. (4/11/24). "Press Release: Idorsia Takes Steps to Address Short-term Liquidity Needs". Allschwil....
• [3] Idorsia Ltd.. (3/20/24). "Press Release: US FDA Approves Idorsia’s Once-daily Tryvio (aprocitentan) – the First and Only Endothelin Receptor Antagonist for the Treatment of High Blood Pressure Not Adequately Controlled in Combination with other Antihy...
• [4] Idorsia Ltd.. (3/18/24). "Press Release: Idorsia and Viatris Successfully Close the Transaction for the Global Research and Development Collaboration". Allschwil....
• [5] Viatris Inc.. (2/28/24). "Press Release: Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance". Pittsburgh, PA....
• [6] Idorsia Ltd.. (2/28/24). "Press Release: Idorsia and Viatris Enter into a Significant Global Research and Development Collaboration". Allschwil....
• [7] Idorsia Ltd.. (7/21/23). "Press Release: Idorsia Announces a Cost Reduction Initiative to Be Implemented by the End of 2023". Allschwil....
• [8] Idorsia Ltd.. (7/20/23). "Press Release: Idorsia Sells Its Asia Pacific (ex-China) Operations – Including Select License Rights to Products – to Sosei Heptares for a Total Consideration of CHF 400 Million". Allschwil....
• [9] Idorsia Ltd.. (6/20/23). "Press Release: Idorsia Has Secured Bridge Financing in the Amount of CHF 75 Million (Ad hoc announcement pursuant to Art. 53 LR)". Allschwil....
• [10] Idorsia Ltd.. (1/9/23). "Press Release: Idorsia Presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 Provide the Foundation for Our Success in 2023". Allschwil....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.